NGEN
NervGen Pharma Corp. Common stock
NASDAQ · Healthcare · Biotechnology · CA
$2.33
+0.43%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +49.3%
- EBIT
- -68.6%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +53.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +76.4%
- EBIT
- -0.7%
- Net income
- -83.9%
- EPS
- -69.4%
- Free cash flow
- -15.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026